Meribank Biotech Co., Ltd (TPEX:4724)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
13.85
+0.70 (5.32%)
Apr 20, 2026, 1:10 PM CST
Market Cap1.29B -14.8%
Revenue (ttm)471.76M +28.7%
Net Income-81.47M
EPS-0.89
Shares Out87.98M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume179,655
Average Volume92,902
Open13.15
Previous Close13.15
Day's Range13.00 - 14.25
52-Week Range12.20 - 24.75
Beta0.49
RSI38.14
Earnings DateMay 14, 2026

About Meribank Biotech

Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services. The company was founded in 2001 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 142
Stock Exchange Taipei Exchange
Ticker Symbol 4724
Full Company Profile

Financial Performance

In 2025, Meribank Biotech's revenue was 471.76 million, an increase of 28.75% compared to the previous year's 366.43 million. Losses were -81.47 million, -13.99% less than in 2024.

Financial Statements